Hide Message

Updating the Resource Centre Digital Platform

The Business & Human Rights Resource Centre is at a critical point in its development. Our digital platform is home to a wealth of information on business and human rights, but hasn’t had a visual refresh for a number of years.

We will soon be updating the site to improve its usability and better serve the thousands of people that use our site to support their work.

Please take an advance peek at our new look, and let us know what you think!

Thank you,
Alex Guy, Digital Officer

Find Out More Hide Message

HC rejects Bayer’s plea [India]

Author: Rupali Mukherjee, Times of India , Published on: 19 August 2009

Promoting consumers access to affordable medicines, the Delhi High Court...rejected pharma MNC Bayer's petition, which had indirectly sought ‘patent linkage'... patent linkages mean that no marketing approval is given for generic versions of medicines, which have been granted a patent in India...While holding that unpatented drugs are not spurious drugs, Justice Ravindra Bhat held that this petition was an attempt to tweak public policy. [refers to Cipla]

Read the full post here

Related companies: Bayer Cipla